Indapta Therapeutics, a biotechnology company developing next-generation differentiated cell therapies for the treatment of cancer and autoimmune diseases, announced that Cancer Prevention and Research Institute of Texas (CPRIT) has granted the company a competitive product development research award. The $4.5M grant will support Indapta’s ongoing clinical development of its lead product, IDP-023, for patients with advanced non-Hodgkin’s lymphoma and multiple myeloma.
Patients enrolled in the Phase I clinical trial to date have received up to three planned doses of IDP-023 with or without interleukin-2. Once safety of multiple doses in combination with interleukin-2 has been established, cohorts of patients with lymphoma and multiple myeloma will receive escalating doses of IDP-023 in combination with the monoclonal antibodies, rituximab and daratumumab, respectively.